• In the most recent quarter, Teladoc Health reported US$642.3 million in revenue, roughly flat year on year but slightly above analyst expectations, while issuing next‑quarter revenue and EBITDA guidance that fell short of forecasts.
• Despite the softer near‑term outlook, Teladoc lifted its full‑year guidance more than any online marketplace peer and grew its user base to 101.8 million, an 8.5% increase that highlights expanding platform reach.
• We’ll now examine how Teladoc’s mix of cautious near‑term guidance and stronger full‑year outlook may reshape its investment narrative.

This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

Teladoc Health Investment Narrative Recap

To own Teladoc, you need to believe virtual care can support a large, engaged user base while gradually improving profitability from today’s losses. The latest quarter’s flat US$642.3 million revenue but higher full year guidance reinforces that story, while the key near term catalyst remains execution in BetterHelp and chronic care. The biggest risk is that competitive and pricing pressure in these areas keeps margins under strain. This quarter’s guidance miss does not fundamentally change that risk, but it keeps it front of mind.

The most relevant recent announcement here is Teladoc’s Q4 2025 and full year 2025 earnings release, which paired slightly higher revenue with a reduced net loss of US$25.1 million for the quarter. Against the softer Q1 2026 outlook, that improvement in losses matters for the catalyst around eventual earnings progress, but it also highlights the trade off: continued investment in product, integrations and scaling BetterHelp insurance could weigh on how quickly those losses narrow.

Yet investors should be aware that the biggest question is what happens if BetterHelp’s shift to insurance fails to offset churn and margin pressure in the core business...

Teladoc Health's narrative projects $2.7 billion revenue and $235.6 million earnings by 2028. This requires 1.9% yearly revenue growth and a $443.0 million earnings increase from -$207.4 million today.

Uncover how Teladoc Health's forecasts yield a $9.12 fair value, a 65% upside to its current price.

Exploring Other Perspectives

Before this report, the most optimistic analysts were counting on Teladoc’s AI driven care orchestration to lift margins, with revenue growing to about US$2.8 billion and earnings reaching roughly US$13.6 million. That is a far more upbeat narrative than consensus, and this quarter’s mix of flat revenue and cautious guidance could either reinforce or challenge those views, so it is worth comparing how your expectations line up with both sets of assumptions.

Explore 2 other fair value estimates on Teladoc Health - why the stock might be worth just $9.12!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Teladoc Health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Teladoc Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teladoc Health's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.